1. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models
- Author
-
Mehibel, Manal, Xu, Yu, Li, Caiyun G., Moon, Eui Jung, Thakkar, Kaushik N., Diep, Anh N., Kim, Ryan K., Bloomstein, Joshua D., Xiao, Yiren, Bacal, Julien, Saldivar, Joshua C., Le, Quynh-Thu, Cimprich, Karlene A., Rankin, Erinn B., and Giaccia, Amato J.
- Subjects
Drug resistance -- Physiological aspects ,Cancer -- Care and treatment ,Hypoxia -- Physiological aspects ,Cancer cells -- Physiological aspects ,Breast cancer -- Physiological aspects -- Models -- Drug therapy ,Health care industry - Abstract
Hypoxia, a hallmark feature of the tumor microenvironment, causes resistance to conventional chemotherapy, but was recently reported to synergize with poly(ADP-ribose) polymerase inhibitors (PARPis) in homologous recombination-proficient (HR-proficient) cells through suppression of HR. While this synergistic killing occurs under severe hypoxia (, Introduction Cytotoxic therapies have long been the backbone of cancer therapy, as they represent an effective means of killing large numbers of tumor cells. A common problem with cytotoxic therapies [...]
- Published
- 2021
- Full Text
- View/download PDF